Pharmacologic and antitumor effects of 1,2:5,6-dianhydrogalactitol (NSC-132313).
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D004988:Ethers, Cyclic / Q000494:pharmacology*; D004376:Galactitol / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D006367:HeLa Cells / Q000187:drug effects; D007928:Lethal Dose 50; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008938:Mitosis / Q000187:drug effects; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010587:Phagocytosis / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D013402:Sugar Alcohols / Q000494:pharmacology*; D013997:Time Factors
D000970:Antineoplastic Agents; D004988:Ethers, Cyclic; D013402:Sugar Alcohols; D004376:Galactitol